A past with uncertainty, a future with hope – rare disease day 2014 from a USA perspective by Stephen C Groft
Groft Orphanet Journal of Rare Diseases 2014, 9:31
http://www.ojrd.com/content/9/1/31EDITORIAL Open AccessA past with uncertainty, a future with hope – rare
disease day 2014 from a USA perspective
Stephen C GroftAbstract
We reflect on the worldwide research accomplishments, orphan product approvals, and the commitments by the
rare diseases community. Major collaborative efforts by the public and private sectors increased interventions and
diagnostics for rare diseases. We marvel at the impact of safe and effective treatments when they become available.
Hope remains for the rare diseases community with a renewed commitment and acceptance of collaborative
public-private partnerships of government translational research and regulatory programs, the biopharmaceutical,
devices and diagnostics industries, academic investigators, and patient advocacy groups. The global rare diseases
community remains strong and responsive to the voices and needs of patients, families, and clinicians awaiting
diagnosis and treatment for their disease. We anticipate even greater successes in 2014 to reflect on Rare Disease
Day 2015.
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out the world, we pause to reflect on the numerous and
impressive research accomplishments and orphan prod-
uct approvals granted during the past year. Not to be
forgotten are the deep commitments required to reach
these goals made by the rare diseases community includ-
ing the pharmaceutical, biotechnology and medical de-
vices and diagnostic industries, philanthropic foundations,
patients and families, medical and scientific advisory
boards associated with patient advocacy groups, the aca-
demic research community, research and regulatory scien-
tists, government funding and regulatory agencies and the
public.
While we marvel at the impact of treatments now
available for many rare diseases, the enthusiasm is tem-
pered by the needs of patients and health care providers
for interventions to become available for conditions.
Despite intensive efforts a lack of an appropriate inter-
vention exists for most rare diseases. The current model
of product development for rare disease interventions is
extremely expensive and time consuming to complete.
Even after the completion of required studies most prod-
ucts are susceptible to failure at different stages of theCorrespondence: Stephen.Groft@nih.gov
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suggest nearly 15 years of research and development
efforts costing over $1 billion are required before the
introduction of a new molecular entity into the market-
place. Even with these significant commitments of time
and financial resources, we continue to achieve a 1%
success rate of a product reaching the patient. This has
resulted in little hope for producing treatments or inter-
ventions for most patients with rare diseases.
The identification of new rare diseases is expected to
continue to grow and surpass the number of new prod-
ucts available for the prevention, diagnosis, or cure of
rare diseases. To meet the prevention, diagnostic and
therapeutic needs of these millions of patients worldwide
with one of approximately 6500 rare diseases and condi-
tions, a systematic and coordinated approach is still re-
quired. The approach will require extensive public-private
partnerships to utilize existing resources and incentives to
stimulate the development of orphan products. This ap-
proach requires not only an acceptance of the premise
that there are tremendous unmet health needs for the mil-
lions of patients with rare diseases and their families but a
renewed commitment to these unmet needs to address
this public health problem worldwide.
Despite these drawbacks, there is hope for the rare
diseases community. In 2013, a survey of current orphanis is an Open Access article distributed under the terms of the Creative
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and Research Manufacturers Association (PhRMA) re-
vealed approximately 454 orphan products were in differ-
ent stages of development. The rare diseases community
awaits the arrival of these products into research clinics
and in the market place for their use. The Office of Orphan
Products Development at the USA FDA provided Orphan
Product Designations for more than 255 possible indica-
tions. The FDA Review Divisions approved products
for 30 rare diseases indications. Regulatory incentives
now provide for bestowing a transferable Rare Pediatric
Diseases Priority Review Voucher similar to Tropical
Diseases Priority Review Voucher for these disorders
when an approval for a product for these conditions is
granted. Other incentives provide for expedited program
development and review include Fast Track Designation,
Priority Review status, accelerated approval, special incen-
tives for development of antibiotics for selected diseases,
and designation as a breakthrough therapy. Each of these
programs includes distinct qualifying criteria and incentives
for the community to become more familiar.
The realization exists for most interventions for rare
diseases that there is an absence of sufficient pre-clinical
and clinical information to enable a potentially useful
product to move forward in the research and develop-
ment continuum. On top of the programmatic and
financial commitments to rare diseases research ($3.623
Billion USD for approximately 9400 research projects)
and orphan drug research ($809 Million USD for 1650
research projects), the National Institutes of Health
(NIH) has initiated new programs and expanded existing
programs to provide the collaborative efforts required to
stimulate product development or provide necessary
data to enable products to move to the next stage of
product development for rare, neglected, and common
diseases. Several NIH institutes and centers have in-
creased their available resources to bridge these data
gaps that currently exist and may provide the traditional
grants and contracts to investigators to complete the
necessary work. Others will continue the collaborative
efforts and provide services and support for the studies
to develop the necessary information leading to a regula-
tory decision. Several of these programs available from the
National Center for Advancing Translational Sciences
including the competition of the Rare Diseases Clinical
Research Network (RDCRN) Consortia, the Therapeutics
for Rare and Neglected Diseases (TRND) and the Bridging
Interventional Development Gaps Programs, the Drug
Repurposing Program, and the Clinical and Translational
Sciences Award (CTSA) program complement other
models of collaborative efforts leading to product develop-
ment. These models include the National Cancer Insti-
tute’s Experimental Therapeutics program (NExT), and
the NeuroNExT program from the National Institute ofNeurological Disorders and Stroke, the Best Pharmaceuti-
cals for Children Act (BPCA) at the National Institute of
Child Health and Human Development and the Centers
for Accelerated Innovation at the National Heart, Lung,
and Blood Institute. Each program offers unique oppor-
tunities and requires discussions and collaborative efforts
with responsible program staff. Growing emphasis on in-
tegrating information from existing and newly created pa-
tient registries and natural history studies will expand the
knowledgebase for a better understanding of rare diseases.
Numerous efforts by the rare diseases community have
resulted in an increase of possible interventions and
diagnostics for rare diseases. With the ready access
and the acceptance of the numerous collaborative ap-
proaches and resources available from many sources,
more rapid development of products will occur. More
recent discoveries of the molecular bases of rare dis-
eases have enabled the identification of many possible
therapeutic interventions. With support provided from
the Common Fund, the Undiagnosed Diseases Pro-
gram at the NIH Clinical Center Hospital will expand
to more academic centers in the USA as a response to
the need for better diagnostic procedures for an esti-
mated 6% to 8% of the population who do not have an
adequate diagnosis for their diseases. We anticipate
the day when clinics dedicated to the diagnosis of rare
diseases will be connected globally. More affordable
access to results of sequencing efforts to establish the
molecular basis of rare, genetic diseases will provide
needed relief to those patients without a diagnosis,
even if interventions are not available.
Challenges still remain such as patient recruitment
from multiple countries, establishing trust in global re-
search partnerships with appropriate sharing of data and
accomplishments, the use of appropriate study design
for studies with small patient populations available for a
study, and the costs of orphan products.
However, optimism prevails as we consider the pos-
sible treatments related to the development of trad-
itional small molecules, enzyme replacement therapies,
monoclonal antibodies, gene and cellular therapies, RNAi
compounds, nanotechnology applications, and precision
or personalized medicines. Establishing and confirming
diagnosis will be improved due to whole genome and
exome sequencing capabilities. These advances and in-
cluding many more rare diseases in the International
Classification of Diseases (ICD 11) should help estab-
lish useful and reliable prevalence figures for rare dis-
eases. Let’s hope that as we celebrate Rare Disease Day
2015 we will look back on Rare Diseases Day 2014 as a
continuation of many activities initiated since 1982.
Recognition and acceptance of the expanding role of
patient advocacy groups and patients/families as research
partners are required for advances with collaborative
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academic research centers, government and foundation
funding sources, and regulatory agencies. We can expect a
continued expansion of public–private partnerships of
government translational research programs with industry
partnerships, and industry partnerships with academic
research centers and patient advocacy groups on a global
basis.
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